UNITEDHEALTH GROUP INC (UNH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for UNH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| UNH | Former Commissioner of the Food and Drug Administration; Director | 53 | ["Extensive clinical, regulatory and health care expertise","23rd Commissioner of the U.S. Food and Drug Administration","Current Senior Fellow at the American Enterprise Institute","Venture capital experience at New Enterprise Associates","Understanding of national health care policy, patient care and complex regulatory environments"] | ["Health and Clinical Practice Policies","Public Responsibility","Health and Clinical Practice Policies Committee","Public Responsibility Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ILMN | Independent Chair | 53 | ["Partner at New Enterprise Associates","senior fellow at AEI","Former FDA Commissioner","Director at Pfizer","United Health","Tempus AI","Extensive policy expertise","Experience as FDA Commissioner (2017-2019)","Senior fellow at AEI","Various roles in public and private sectors","Venture Partner at New Enterprise Associates (2007 – 2017)","FDA Deputy Commissioner for Medical and Scientific Affairs (2005 – 2007)","Senior Advisor for Medical Technology to the FDA Commissioner (2003 – 2004)","Columnist for Wall Street Journal","Contributor to CNBC and CBS Face the Nation","Elected Member of the National Academy of Medicine","Director at United Health","Director at Tempus AI"] | ["Nominating/Corporate Governance"] | 2026 |
| TEM | Director | 53 | ["Member of board of directors since October 2019","Partner on NEA’s healthcare investment team since April 2019","Resident Fellow at American Enterprise Institute since April 2021","23rd Commissioner of the U.S. Food and Drug Administration from May 2017 to April 2019","Venture Partner at NEA from January 2007 to May 2017","Senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004","Contributor to CNBC and CBS News program Face the Nation","Executive committee member of Mount Sinai Health System’s board of directors","Co-chair of board’s education committee","Board member of Wesleyan University","Holds a B.A. from Wesleyan University and an M.D. from Mount Sinai School of Medicine","Extensive experience as a medical policy expert and public health advocate"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| PFE | Director; Chair; Committee Member | 51 | ["Government & Public Policy","Medicine & Science","Healthcare & Pharma"] | ["Chair","Regulatory and Compliance","Science and Technology","Regulatory and Compliance Committee","Science and Technology Committee"] | 2024 |
Biography sourced from the proxy statement filing.
Director Since: 2025 Age: 53 Committees: Health and Clinical Practice Policies Public Responsibility Other Public Directorships: Pfizer, Inc. Tempus AI, Inc. Illumina, Inc. Expertise Provided to the Board: Dr. Scott Gottlieb has extensive clinical, regulatory and health care expertise, drawn from his distinguished career in public service and the private sector. As the 23rd Commissioner of the U.S. Food and Drug Administration, and current Senior Fellow at the American Enterprise Institute, Dr. Gottlieb possesses a unique understanding of national health care policy, patient care and complex regulatory environments. Dr. Gottlieb s public service, coupled with venture capital experience at New Enterprise Associates, strengthens the Board s oversight of health care innovation, corporate strategy and the complex regulatory environment. Career Highlights: 2019 to Current: Senior Fellow at the American Enterprise Institute 2019 to Current: Special Partner at New Enterprise Associates 2003 to 2019: Served in numerous roles with increasing responsibility at the U.S. Food & Drug Administration, including: 2017 to 2019: Commissioner 2005 to 2007: Deputy Commissioner for Medical and Scientific Affairs 2004: Director of Medical Policy Development 2003 to 2004: Senior Advisor to the Commissioner for Medical Technology Skills and Qualifications : Capital Markets Clinical Practice Corporate Governance Digital Communication Finance Government & Regulatory Health Care Industry Large Complex Organizations Technology / Business Processes